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Abstract
Background: A recent randomized placebo-controlled trial of the effect of atorvastatin treatment on the progression of
newly diagnosed type 1 diabetes suggested a slower decline of residual beta cell function with statin treatment. Aim of this
secondary analysis was to identify patient subgroups which differ in the decline of beta cell function during treatment with
atorvastatin.
Methodology/Principal Findings: The randomized placebo-controlled Diabetes and Atorvastatin (DIATOR) Trial included
89 patients with newly diagnosed type 1 diabetes and detectable islet autoantibodies (mean age 30 years, 40% females),
in 12 centers in Germany. Patients received placebo or 80 mg/d atorvastatin for 18 months. As primary outcome
stimulated serum C-peptide levels were determined 90 min after a standardized liquid mixed meal. For this secondary
analysis patients were stratified by single baseline characteristics which were considered to possibly be modified by
atorvastatin treatment. Subgroups defined by age, sex or by baseline metabolic parameters like body mass index (BMI),
total serum cholesterol or fasting C-peptide did not differ in C-peptide outcome after atorvastatin treatment. However,
the subgroup defined by high (above median) baseline C-reactive protein (CRP) concentrations exhibited higher
stimulated C-peptide secretion after statin treatment (p=0.044). Individual baseline CRP levels correlated with C-peptide
outcome in the statin group (r
2=0.3079, p,0.004). The subgroup with baseline CRP concentrations above median
differed from the corresponding subgroup with lower CRP levels by higher median values of BMI, IL-6, IL-1RA, sICAM-1
and E-selectin.
Conclusions/Significance: Atorvastatin treatment may be effective in slowing the decline of beta cell function in a patient
subgroup defined by above median levels of CRP and other inflammation associated immune mediators.
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Introduction
Treatment with statins has been found to dampen inflammatory
reactions and immune activation in general, and some positive
results have also been reported for intervention trials in
rheumatoid arthritis [1,2,3]. Most studies of statin treatment in
animal models of immune destruction of beta cells also observed
some protection of beta cells or improved regeneration [4,5,6,7,8].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33108In a recent trial of atorvastatin in patients with newly diagnosed
type 1 diabetes (Diabetes and Atorvastatin, DIATOR) the primary
analysis did not show a significant effect of statin treatment on the
progressive loss of beta cell function at 18 months, as determined
from serum C-peptide concentrations after a standardized liquid
mixed meal [9]. However, descriptive analyses suggested a slower
decline of fasting and meal-stimulated C-peptide concentrations in
patients of the atorvastatin group, suggesting better preservation of
beta-cell function over the 18 months of the trial. We therefore
performed a secondary analysis of the data set in order to identify
a patient subgroup with improved preservation of residual C-
peptide secretion in response to atorvastatin treatment.
Results
Patients were stratified by single baseline characteristics which
were considered to possibly associate with atorvastatin treatment.
These characteristics comprised basic anthropomorphic, metabol-
ic and immune parameters. For each parameter patients with
baseline values at or below the median were compared with those
above the median. Alternatively, patients were stratified according
to sex. Pre-defined primary outcome measure was the median
stimulated C-peptide concentration at 18 months. In the placebo
group, C-peptide outcome was dependent on some baseline
metabolic parameters, i.e., significantly higher median stimulated
C-peptide concentrations at 18 months were observed in
subgroups defined by lower BMI, higher fasting or higher
stimulated C-peptide levels at baseline (Table 1). In the
atorvastatin group, there was less association with baseline
metabolic parameters, only higher stimulated C-peptide secretion
at baseline predicted better C-peptide outcome at 18 months. Of
two clinically relevant targets of statin action, total cholesterol and
CRP, baseline CRP levels associated with C-peptide outcome.
This means there was a lower decline of C-peptide secretion in the
subgroup with higher baseline CRP concentrations. No associa-
tion with outcome was seen for patient subgroups defined by
higher vs. lower baseline IL-6 concentrations (Table 1). For each
single characteristic association with outcome was calculated with
adjustments for all other baseline parameters indicated in the
table.
To study the association between baseline CRP concentrations
and C-peptide outcome in more detail, single patient data are
depicted in Fig. 1 in the format of a Pearson’s correlation test.
There was a significant linear correlation between baseline CRP
concentrations and C-peptide outcome in the statin group but not
the placebo group (r
2=0.3079, p,0.004) (Fig. 1A). Only two out
of 13 patients with high CRP baseline levels had stimulated C-
peptide concentrations below the median of the subgroup with low
baseline levels (median 0.40 nmol/l). Baseline cholesterol levels
and C-peptide outcome were not associated (Fig. 1B).
Both targets of statins, total cholesterol and CRP levels, were
lowered by atorvastatin treatment, while IL-6 concentrations were
not modified (Table 2). Total cholesterol levels were decreased in
both subgroups, in those with initially high or with initially low
total cholesterol levels. CRP levels were reduced (p=0.037) upon
atorvastatin treatment only in the patient subgroup with initially
high (above median) CRP concentrations (Table 2). However, the
extent of CRP level lowering by atorvastatin was not associated
with the extent of residual C-peptide secretion after 18 months
(Fig. 2A). The extent of cholesterol level lowering also did not
correlate with C-peptide outcome (Fig. 2B).
Since of all parameters analyzed, only baseline CRP levels
were associated with preservation of C-peptide secretion in the
statin group, we compared the subgroup with higher versus
lower baseline CRP concentrations for other characteristics. As
shown in Table 3, patients with higher CRP levels also
exhibited greater median concentrations for the inflammation-
associated immune mediators IL-6 (p=0.021), IL-1RA
(p=0.036), sICAM-1 (p=0.016) and E-selectin (p=0.034).
However, there was no general immune activation because
Table 1. Baseline characteristics of patients versus outcome.
Placebo Atorvastatin
Baseline characteristic C-peptide* P-value Baseline characteristic C-peptide* P-value
Age below median 0.36 [0.58] n.s. Age below median 0.53 [0.87] n.s.
above median 0.69 [0.92] above median 0.72 [0.70]
Sex male 0.42 [0.80] n.s. Sex male 0.73 [0.94] n.s.
female 0.57 [0.77] female 0.58 [0.98]
BMI below median 0.81 [0.68] 0.023 BMI below median 0.73 [0.96] n.s.
above median 0.29 [0.34] above median 0.67 [0.92]
Fasting C-peptide below median 0.40 [0.46] 0.011 Fasting C-peptide below median 0.27 [0.74] n.s.
above median 0.85 [1.17] above median 0.82 [0.69]
Stimulated C-peptide below median 0.34 [0.36] 0.0007 Stimulated C-peptide below median 0.26 [0.72] 0.031
above median 0.93 [1.05] above median 0.82 [0.66]
Total cholesterol below median 0.50 [0.79] n.s. Total cholesterol below median 0.79 [0.87] n.s.
above median 0.40 [0.84] above median 0.69 [0.70]
CRP below median 0.66 [0.65] n.s. CRP below median 0.40 [0.75] 0.044
above median 0.42 [1.18] above median 0.76 [0.76]
IL-6 below median 0.40 [0.62] n.s. IL-6 below median 0.73 [0.86] n.s.
above median 0.50 [1.07] above median 0.58 [0.76]
*- the column shows stimulated C-peptide concentrations at 18 months (nmol/l) [IQR].
Data are presented as median concentrations and interquartile range [IQR].
doi:10.1371/journal.pone.0033108.t001
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concentrations in circulation (IFN-c, IL-18, MCP-1, IP-10,
MCP-4, MIP-1ß, MDC, IL-8, TARC). Patients with higher
baseline CRP concentrations had higher median BMI and
fasting C-peptide levels (Table 3).
Discussion
The primary analysis of the DIATOR trial did not find a
significant effect of atorvastatin treatment on stimulated C-peptide
concentrations at 18 months, although median C-peptide values
Figure 1. Correlation analysis of baseline CRP or total serum cholesterol concentrations with C-peptide outcome. Of individual
patients, baseline CRP concentrations (a) or baseline total cholesterol levels (b) were compared to stimulated C-peptide concentrations at 18 months
(18 m). The vertical line indicates the median of baseline CRP or cholesterol concentrations, respectively, the red line indicates the linear regression
line obtained by the Pearson’s correlation test.
doi:10.1371/journal.pone.0033108.g001
Table 2. Effect of atorvastatin treatment on levels of cholesterol and immune mediators.
Parameter Placebo (median) [IQR] Atorvastatin (median) [IQR]
Total cholesterol (mmol/l) At baseline 4.02 [1.03] n.s. 3.93 [0.96] p,0.0001
At 3 months 3.89 [1.13] 2.56 [0.78]
CRP (mg/l) At baseline 0.84 [2.24] n.s. 0.86 [2.17] p=0.029
At 3 months 0.64 [1.41] 0.69 [1.07]
IL-6 (pg/ml) At baseline 0.58 [0.54] n.s. 0.75 [1.08] n.s.
At 3 months 0.67 [0.50] 0.56 [1.62]
Cholesterol above baseline median At baseline 4.53 [0.70] n.s. 4.33 [0.57] p,0.0001
At 3 months 4.44 [0.96] 2.94 [0.61]
Cholesterol below baseline median At baseline 3.57 [0.39] n.s. 3.39 [0.69] p,0.0001
At 3 months 3.47 [0.63] 2.35 [0.76]
CRP above baseline median At baseline 2.55 [2.75] n.s. 2.37 [1.90] p=0.037
At 3 months 1.73 [3.39] 1.24 [0.86]
CRP below baseline median At baseline 0.33 [0.23] n.s. 0.24 [0.40] n.s.
At 3 months 0.36 [0.31] 0.21 [0.34]
doi:10.1371/journal.pone.0033108.t002
Atorvastatin in Type 1 Diabetes
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placebo group [9]. The underlying reason was a large range of C-
peptide concentrations among patients at 18 months, varying from
0.1 to 2.3 nmol/l. Because of this apparent heterogeneity we
investigated whether baseline patient parameters characterize
those with good preservation of beta cell function when treated
with atorvastatin from those with less preservation.
There was no association between atorvastatin treatment
outcome and age or sex. Of the metabolic parameters analyzed,
only liquid-mixed meal stimulated C-peptide levels at baseline was
associated with outcome. I.e., patients with above median levels of
stimulated C-peptide at baseline exhibited higher stimulated C-
peptide levels at 18 months of statin treatment than patients with
baseline levels below the median (p,0.031). The same association
was observed in the placebo group, suggesting that the association
of baseline stimulated C-peptide secretion with C-peptide outcome
is independent of atorvastatin treatment. Indeed, it has been
reported previously that there is a positive association between the
level of C-peptide secretion at diagnosis of type 1 diabetes and
residual beta cell function measured in later years [10,11,12].
Two major factors modulated by statin treatment are serum
cholesterol and CRP. Both, total serum cholesterol and CRP
concentrations were lowered significantly by atorvastatin treat-
ment. Other lipid parameters such as LDL-cholesterol, HDL-
cholesterol and triglyceride concentrations were also modulated by
atorvastatin as expected [9] and therefore were not analyzed
separately. However, there was no association between baseline
levels of total serum cholesterol and C-peptide outcome, and
Figure 2. Correlation analysis of atorvastatin effects on cholesterol or CRP levels with C-peptide outcome. Of individual patients, the
change of CRP concentrations (a) or total cholesterol concentrations (b) from baseline to 3 months of atorvastatin treatment (‘‘delta’’) were compared
to stimulated C-peptide concentrations at 18 months (18 m).
doi:10.1371/journal.pone.0033108.g002
Table 3. Characteristics of atorvastatin subgroups with lower vs. higher baseline CRP levels.
Characteristic Baseline CRP below median Baseline CRP above media P-value
Median age, y [IQR] 27 [12.5] 36 [8.0] 0.0056
Men, n (%) 13 (72) 7 (41) n.s.
Median BMI (kg/m
2) [IQR] 22.5 [3.9] 25.6 [4.5] 0.0002
Median fasting C-peptide (nmol/l) [IQR] 0.34 [0.22] 0.46 [0.37] 0.019
Median stim. C-peptide (nmol/l) [IQR] 0.78 [0.63] 1.11 [0.77] n.s.
IL-6 (pg/ml) [IQR] 0.50 [0.54] 1.01 [0.95] 0.021
IFN-c (pg/ml) [IQR] 2.53
a [2.55] 1.92
b [0.89] n.s.
IL-18 (pg/ml) [IQR] 131 [105] 107 [52] n.s.
IL-1RA (pg/ml) [IQR] 263 [166] 380 [306] 0.036
MCP-1 (pg/ml) [IQR] 367 [347] 362 [182] n.s.
IP-10 (pg/ml) [IQR] 150
a [82] 144
b [57] n.s.
MCP-4 (pg/ml) [IQR] 319
a [180] 363
b [140] n.s.
MIP-1ß (pg/ml) [IQR] 616
a [404] 751
b [493] n.s.
MDC (pg/ml) [IQR] 4841
a [2137] 5049
b [4562] n.s.
IL-8 (pg/ml) [IQR] 3.00
a [2.72] 3.86
b [4.72] n.s.
TARC (pg/ml) [IQR] 465
a [411] 305
b [307] n.s.
sICAM-1 (ng/ml) [IQR] 162 [77] 201 [82] 0.016
E-selectin (ng/ml) [IQR] 29.95 [19.95] 39.70 [14.60] 0.034
aData available for 15 of 18 patients.
bData available for 15 of 17 patients.
Subgroups were compared for single characteristics without adjustments for differences in other characteristics, in order to describe all differences observed.
doi:10.1371/journal.pone.0033108.t003
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and C-peptide outcome.
The positive correlation between baseline CRP concentrations
and C-peptide outcome in the patients of the statin group was not
seen in those of the placebo group. At baseline, CRP concentra-
tions ranged from 0.08 to 6.34 mg/l in patients of the statin group,
and those patients with values above the median of 0.86 mg/l
exhibited significantly higher stimulated C-peptide levels at 18
months than those with initially low CRP levels. Interestingly,
there was no correlation between the extent of CRP level lowering
by atorvastatin and C-peptide outcome. This suggests that
increased CRP concentrations at baseline are a marker of
responsiveness to atorvastatin treatment, but that the degree of
CRP level lowering is not directly involved in the better
preservation of beta cell function in response to atorvastatin.
Interestingly, an anti-inflammatory CRP-lowering activity of
atorvastatin was observed in a study of type 2 diabetes patients
only for the subgroup with increased levels of CRP (.2 mg/l)
[13].
Most pharmacological effects of statins are due to inhibiting
hydroxyl-3-methylglutaryl-coenzyme A reductase. As a conse-
quence, less mevalonate is available for the synthesis of cholesterol.
An impaired mevalonate pathway causes lower production of
farnesyl or geranylgeranyl pyrophosphates which can modify
several transcription factors controlling cell growth, endothelial
activity and immune gene expression [14,15,16,17]. At the level of
the immune system, statins decreased expression of several pro-
inflammatory mediators and receptors [18,19,20,21]. This is
accompanied by dampening of aggressive Th1-type and promo-
tion of more benign Th2-type T cell responses [22,23,24]. Another
relevant target is the endothelium where atorvastatin suppresses
inflammatory reactivity and promotes NO bioavailability
[25,26,27,28]. It therefore was of interest to compare additional
immune characteristics between the subgroup with ‘‘high’’ versus
‘‘low’’ baseline CRP levels. The comparison of serum concentra-
tions of 13 immune mediators indicated significantly higher
concentrations of IL-6, IL-1RA, sICAM-1 and E-selectin in the
‘‘high’’ CRP subgroup. For the 10 other pro- or anti-inflammatory
immune mediators analyzed, no difference was found between the
two subgroups. This indicates that there is no general immune
activation in association with increased CRP levels.
Elevated concentrations of IL-6 in the ‘‘high’’ CRP subgroup
represent a confirmatory finding because IL-6 is the major internal
inductor of CRP production [29] and a correlation between
systemic CRP and IL-6 levels has been reported previously [30].
Increased levels of IL-6, IL-1RA, sICAM-1 and E-selection in the
‘‘high’’ CRP group are reminiscent of subclinical systemic
inflammation seen in obesity, metabolic syndrome or type 2
diabetes [31,32,33,34]. Hence the ‘‘high’’ CRP subgroup may
represent a subgroup among patients with type 1 diabetes which
may share some features with type 2 diabetes. Such an
interpretation is supported by the observation that patients with
‘‘high’’ CRP levels had a significantly higher BMI and fasting C-
peptide concentrations. A positive association of CRP levels with
BMI at diagnosis of type 1 diabetes was already noted in a
previous study [35].
In conclusion, a higher than median level of plasma CRP at
baseline is associated with better preservation of beta cell function
in newly diagnosed patients with type 1 diabetes treated with
atorvastatin while such an association is not seen in patients in the
placebo group. Further analysis of this putative atorvastatin-
response subgroup showed characteristics of systemic subclinical
inflammation as seen in type 2 diabetes, increased BMI, higher
levels of fasting C-peptide and, besides CRP, higher systemic
concentrations of IL-6, IL-1RA, sICAM-1 and E-selectin.
Methods
Trial procedure and laboratory analyses
In the randomized controlled German multi-center trial
DIATOR patients with newly diagnosed type 1 diabetes and at
least one islet autoantibody (to glutamic acid decarboxylase 65 or
to insulinoma-associated antigen 2, or islet cell antibodies), age 18–
39 years received either placebo or atorvastatin for 18 months.
The starting atorvastatin dose was 40 mg/d which was increased
to 80 mg/d after 4 weeks. For a detailed description of the trial,
including the ethics statement see ref. [9].
Stimulated C-peptide secretion was assessed using serum C-
peptide concentrations after a standardized liquid mixed meal
(Boost HPH (Mead Johnson, Evansville, IN, USA), 6 ml per kg
body weight with a maximum of 360 ml) [36]. C-peptide was
measured in serum by an immunoenzymatic assay (Biosource/
Invitrogen, Karlsruhe, Germany), plasma C-reactive protein
(CRP) concentrations were determined by an immunonephelo-
metric assay [37]. All other immune mediators (IL-1RA, IL-6, IL-
8, IL-18, IFN-c, IP-10, MCP-1, MCP-4, MDC, MIP-1b,E -
selectin, sICAM-1 and TARC) were determined by double-
antibody ELISA or bead-based multiplex technology as described
previously [38].
Statistical Analysis
The statistical analyses were performed with SAS (Version 9.2)
and GraphPad Prism (Version 4). Kolmogorov-Smirnov test was
performed to determine whether the distribution is normal. For
comparison of continuous variables Mann-Whitney U test and
unpaired t-test were used. Association of stimulated C-peptide
concentrations at 18 months (dependent variable) with the
corresponding baseline parameters were evaluated using multi-
variate regression models adjusted for age, sex, BMI, fasting C-
peptide, stimulated C-peptide, CRP, and IL-6 as appropriate
(independent variables; all baseline). Univariate correlation
analyses between stimulated C-peptide and total cholesterol or
CRP concentrations were performed using Spearman’s or
Pearson’s correlation as appropriate.
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